Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Market Closed 03-13 16:00:00 EDT

3.42

+0.13

+3.95%

盘后3.40

-0.02-0.58%

19:59 EDT

High3.52	Low3.35	Vol14.41M
Open3.35	D1 Closing3.29	Amplitude5.32%
Mkt Cap1.80B	Tradable Cap1.42B	Total Shares527.40M
T/O49.21M	T/O Rate3.47%	Tradable Shares415.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":3.42,"timestamp":1773432000000,"preClose":3.29,"halted":0,"volume":14409835,"hourTrading":{"tag":"盘后","latestPrice":3.4,"preClose":3.42,"latestTime":"19:59 EDT","volume":169664,"amount":578936.4691,"timestamp":1773446373176,"change":-0.02,"changeRate":-0.005848,"amplitude":0.014415},"delay":0,"changeRate":0.039513677811550116,"floatShares":415000000,"shares":527397997,"eps":-1.440975,"marketStatus":"Market Closed","change":0.13,"latestTime":"03-13 16:00:00 EDT","open":3.35,"high":3.52,"low":3.345,"amount":49211835.9002435,"amplitude":0.053191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.440975,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":3.29,"preHourTrading":{"tag":"盘前","latestPrice":3.35,"preClose":3.29,"latestTime":"09:29 EDT","volume":68304,"amount":226142.659104,"timestamp":1773408556898,"change":0.06,"changeRate":0.018237,"amplitude":0.027356},"postHourTrading":{"tag":"盘后","latestPrice":3.4,"preClose":3.42,"latestTime":"19:59 EDT","volume":169664,"amount":578936.4691,"timestamp":1773446373176,"change":-0.02,"changeRate":-0.005848,"amplitude":0.014415},"volumeRatio":1.062683727574303,"impliedVol":0.785,"impliedVolPercentile":0.1076},"requestUrl":"/m/hq/s/RXRX","defaultTab":"news","newsList":[{"id":"2618900073","title":"A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2618900073","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618900073?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:21","pubTimestamp":1773296482,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) has drawn fresh attention after reporting Q4 revenue above consensus, highlighting progress in its AI-native drug discovery platform and a cash runway that management says extends into early 2028.\nSee our latest analysis for Recursion Pharmaceuticals.\nDespite the strong Q4 update and progress across its AI-native programs, Recursion Pharmaceuticals’ share price return has been weak, with a 30 day share price return decline of 10.39% and a 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/a-look-at-recursion-pharmaceuticals-rxrx-valuation-after-q4","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/a-look-at-recursion-pharmaceuticals-rxrx-valuation-after-q4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","RXRX","BK4588","BK4609","AIYY","BK4543","LU2065732104.USD","BK4611","BK4139","BK4023","BK4585","AI","BK4097","BK4587","BK4548","BK4539","BK4528"],"gpt_icon":0},{"id":"2618979957","title":"Recursion Pharmaceuticals CEO and President Najat Khan Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618979957","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618979957?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:42","pubTimestamp":1773265320,"startTime":"0","endTime":"0","summary":"Najat Khan, CEO and President and a director of Recursion Pharmaceuticals Inc., reported a disposal of the company’s Class A common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL4mhvTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals CEO and President Najat Khan Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4609","BK4539","BK4548","BK4139"],"gpt_icon":0},{"id":"2617650153","title":"Insiders Cash Out: GE Vernova, Recursion, Axon, Seagate, Energy Fuels","url":"https://stock-news.laohu8.com/highlight/detail?id=2617650153","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617650153?lang=en_us&edition=fundamental","pubTime":"2026-03-07 21:01","pubTimestamp":1772888492,"startTime":"0","endTime":"0","summary":"Insiders have been trading these 5 stocks: (($GEV)), (($RXRX)), (($AXON)), (($STX)) and (($UUUU)). Here is a breakdown of their recent trades and t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/insiders-cash-out-ge-vernova-recursion-axon-seagate-energy-fuels?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/insiders-cash-out-ge-vernova-recursion-axon-seagate-energy-fuels?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0943347566.SGD","LU0354030438.USD","LU1066051498.USD","LU0354030511.USD","LU0820561909.HKD","BK4543","BK4609","LU1261432733.SGD","LU0157215616.USD","AXON","LU1064131342.USD","LU2087625088.SGD","LU2756315318.SGD","LU1119994496.HKD","UUUG","LU2168564495.EUR","LU2168564222.USD","BK4585","LU2168564065.EUR","GEV","LU0149725797.USD","BK4566","BK4187","LU0868494617.USD","LU1066051811.HKD","LU0353189763.USD","LU1066051225.USD","LU0689472784.USD","BK4501","LU0353189680.USD","LU1084165304.USD","LU2756315664.SGD","LU1093756168.USD","LU2168564149.EUR","LU0077335932.USD","RXRX","LU1366192091.USD","LU1366333091.USD","LU0267386448.USD","LU1066053197.SGD","BK4548","BK4156","BK4606","LU0640476718.USD","LU0820561818.USD","LU1093756325.SGD","LU1551013342.USD","LU0820562030.AUD","LU1280957306.USD","LU1551013425.SGD","LU1988902786.USD","BK4588","BK4539","BK4206","UUUU","BK4611","STX","LU2168563687.JPY","LU2543165471.USD","LU2264538146.SGD","BK4139"],"gpt_icon":0},{"id":"2617971656","title":"Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2617971656","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617971656?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:19","pubTimestamp":1772842764,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals’ lat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-earnings-call-highlights-ai-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-earnings-call-highlights-ai-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4611","BK4548","BK4139","RXRX","BK4609"],"gpt_icon":0},{"id":"2617756123","title":"Recursion Pharmaceuticals Director Blake Borgeson Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617756123","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617756123?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:39","pubTimestamp":1772660363,"startTime":"0","endTime":"0","summary":"Blake Borgeson, a director of Recursion Pharmaceuticals Inc., reported a disposal of the company’s Class A common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLbW5l2y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals Director Blake Borgeson Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4539","BK4609","RXRX","BK4548","BK4139"],"gpt_icon":0},{"id":"1197289820","title":"Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday Amid Nvidia Concept Stocks Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1197289820","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197289820?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:26","pubTimestamp":1772637998,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price soar 5.08% during intraday trading on Wednesday, marking a significant upward movement.The surge appears to be part of a broader rally in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RXRX"],"gpt_icon":1},{"id":"1129706717","title":"Nvidia Concept Stocks Rally. Nebius Up 9%; Applied Digital And CoreWeave Up 8%; WhiteFiber Up 7%; Core Scientific Up 6%; WeRide And Recursion Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129706717","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129706717?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:11","pubTimestamp":1772637071,"startTime":"0","endTime":"0","summary":"Nvidia Concept Stocks Rally. Nebius Up 9%; Applied Digital And CoreWeave Up 8%; WhiteFiber Up 7%; Core Scientific Up 6%; WeRide and Recursion Up 4%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ac894a37bbfa4eb7c631d98651279a66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUR","APLD","CRNC","NBIS","MU","SERV","SOUN","NVDA","INVZ","RXRX","ARBE","NNOX","CRWV","ARM","TM"],"gpt_icon":0},{"id":"2614866651","title":"Recursion Pharmaceuticals Publishes 2025 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2614866651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614866651?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:47","pubTimestamp":1772214434,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. published a 2025 shareholder letter outlining business updates and priorities for 2026 and beyond. The letter reports an AI-enabled clinical proof of concept in familial adenomatous polyposis for REC-4881 and states that five clinical programs are advancing with defined differentiation and go/no-go criteria. The letter also cites more than $500 million in upfront and progress-based milestone payments to date from partnerships, including $213 million in cash inflows from Roche and Genentech and $134 million in cash inflows from Sanofi. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3mX09H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","BK4539","BK4611","BK4139","RXRX"],"gpt_icon":1},{"id":"1195580149","title":"Nvidia-Linked Shares Fall. CoreWeave Plunged over 17%; Nebius Down 8%; APLD Down 5%; Nvidia Down 2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195580149","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195580149?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:38","pubTimestamp":1772203090,"startTime":"0","endTime":"0","summary":"Nvidia-linked shares fell on Friday. CoreWeave plunged over 17%; Nebius down 8%; APLD down 5%; Nvidia down 2.5%.$CoreWeave(CRWV)$ expects capital expenditure to double this year, it said on Thursday,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"117a4290f3fb77553df3afbd7ffdef06","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARM","INVZ","NBIS","MU","SOUN","ARBE","CRNC","APLD","NNOX","TM","NVDA","AUR","SERV","RXRX"],"gpt_icon":1},{"id":"2614043895","title":"Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2614043895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614043895?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:35","pubTimestamp":1772105700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 06:35 ET (11:35 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4609","BK4539","BK4548","BK4139"],"gpt_icon":0},{"id":"2614695043","title":"Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614695043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614695043?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:32","pubTimestamp":1772105527,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Neutral rating on the shares. The firm revised i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-6-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-6-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4611","BK4548","BK4609","RXRX","BK4139"],"gpt_icon":0},{"id":"2614069711","title":"Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated","url":"https://stock-news.laohu8.com/highlight/detail?id=2614069711","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614069711?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:25","pubTimestamp":1772069133,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan has reiterated their neutral stance on RXRX stock, giving a Hold rating yesterday. Alec Stranahan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-keeps-recursion-at-hold-as-key-clinical-catalysts-remain-longer-dated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-keeps-recursion-at-hold-as-key-clinical-catalysts-remain-longer-dated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU1506573853.SGD","LU0070302665.USD","BK4609","LU0787776722.HKD","LU0149725797.USD","LU0256863811.USD","LU1267930227.SGD","LU0320765489.SGD","LU1366192091.USD","LU1496350171.SGD","LU0648001328.SGD","LU0234572021.USD","LU0971096721.USD","LU0417517546.SGD","LU0640476718.USD","LU1162221912.USD","BK4581","LU1880398554.USD","BK4504","LU1201861165.SGD","LU0106831901.USD","LU0052756011.USD","BK4553","IE0001KFT4U8.USD","LU0211331839.USD","LU1363072403.SGD","LU0306806265.USD","BK4585","LU0130517989.USD","LU0477156953.USD","LU0683600562.USD","IE0034235188.USD","IE00BFXG1179.USD","BK4548","LU0203347892.USD","LU1069347547.HKD","LU1280957306.USD","LU2129689605.HKD","BK4539","BK4611","LU0648000940.SGD","LU2133065610.SGD","LU1880398471.USD","LU0053666078.USD","IE00BLSP4452.SGD","LU1035773651.USD","BK4534","LU1883839398.USD","LU0314106906.USD","LU0310800965.SGD","LU2129689431.USD","LU0868494617.USD","IE00BZ1G4Q59.USD","LU2129689514.USD","IE0002270589.USD","LU0130102774.USD","IE00B19Z3B42.SGD","LU1804176565.USD","LU1496350502.SGD","LU0130518102.USD","LU0130103400.USD","LU0203345920.USD","IE00B1BXHZ80.USD","BK4139","BK4559","LU1668664300.SGD","LU0320765646.SGD","LU0098860793.USD","IE00BKVL7J92.USD","LU0128525689.USD","IE00B19Z3581.USD","LU1074936037.SGD","LU2265009873.SGD","LU0980610538.SGD","LU0321505868.SGD","RXRX","IE00BBT3K403.USD","LU1791807156.HKD","LU0256863902.USD","LU1894683264.USD","IE00B7SZLL34.SGD","LU0477156797.USD","LU0306807586.USD","LU1201861249.SGD","LU1718418525.SGD","LU0170899867.USD","IE00BLSP4239.USD","LU0208291251.USD","LU0321505439.SGD","BK4588","LU1894683348.USD"],"gpt_icon":0},{"id":"2614805310","title":"Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614805310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614805310?lang=en_us&edition=fundamental","pubTime":"2026-02-26 04:00","pubTimestamp":1772049624,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Recursion Pharmaceuticals (RXRX – Research Report) and Penumbra (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-penumbra-pen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-penumbra-pen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4611","PEN","BK4137","BK4581","BK4609","XBI","BK4539","LU0128526141.USD","LU0029874061.USD","RXRX","BK4082","BK4588","BK4139","BK4585","LABU"],"gpt_icon":0},{"id":"2614303929","title":"What's Behind The Jump In Recursion Pharmaceuticals Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303929","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614303929?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:54","pubTimestamp":1772034840,"startTime":"0","endTime":"0","summary":"Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/25/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/25/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50854848/whats-behind-the-jump-in-recursion-pharmaceuticals-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50854848/whats-behind-the-jump-in-recursion-pharmaceuticals-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","BK4611","BK4548","BK4139","RXRX","BK4609"],"gpt_icon":1},{"id":"2614808951","title":"Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2614808951","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614808951?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:54","pubTimestamp":1772020454,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  reported a Q4 loss Wednesday of $0.21 per diluted share, narrowing from a loss of $0.53 a year earlier.Analysts polled by FactSet expected a loss of $0.31.Revenue for the quarter ended Dec. 31 was $35.5 million, up from $4.5 million a year earlier.Analysts surveyed by FactSet expected $24.5 million.As of Dec. 31, Recursion said it had $753.9 million in cash and cash equivalents, which it expects to provide it with a cash runway through early 2028.Shares of the company were up more than 12% in recent Wednesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4611","RXRX","BK4139","BK4548","BK4609"],"gpt_icon":1},{"id":"2614089881","title":"Recursion Pharmaceuticals Inc - May Sell Class a Stock up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089881?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:46","pubTimestamp":1772020019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4611","BK4548","BK4139","RXRX","BK4609"],"gpt_icon":0},{"id":"2614108608","title":"Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2614108608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614108608?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:44","pubTimestamp":1772019858,"startTime":"0","endTime":"0","summary":"Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi paymentsOverviewClinical stage TechBio firm's Q4 operating revenue beat analyst expectationsNet income for Q4 exceeded analyst estimatesCom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL1N3ZL0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4539","BK4609","RXRX","BK4548","BK4139"],"gpt_icon":1},{"id":"2614086139","title":"Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086139","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086139?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:37","pubTimestamp":1772019448,"startTime":"0","endTime":"0","summary":"Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50843855/recursions-2025-cash-balance-was-753-9m-with-expected-cash-runway-extending-into-early-2028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","BK4139"],"gpt_icon":0},{"id":"2614086196","title":"Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086196","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086196?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:37","pubTimestamp":1772019435,"startTime":"0","endTime":"0","summary":"Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4609","RXRX","BK4539","BK4611","BK4548"],"gpt_icon":0},{"id":"1155956762","title":"Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1155956762","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155956762?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:34","pubTimestamp":1772019271,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biotechnology company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RXRX"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0782},{"period":"3month","weight":-0.2102},{"period":"6month","weight":-0.2919},{"period":"1year","weight":-0.4242},{"period":"ytd","weight":-0.1638}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035717},{"month":2,"riseRate":0.4,"avgChangeRate":0.049361},{"month":3,"riseRate":0,"avgChangeRate":-0.230145},{"month":4,"riseRate":0.25,"avgChangeRate":-0.144468},{"month":5,"riseRate":0.4,"avgChangeRate":0.084296},{"month":6,"riseRate":0.6,"avgChangeRate":0.136566},{"month":7,"riseRate":0.8,"avgChangeRate":0.206054},{"month":8,"riseRate":0.2,"avgChangeRate":-0.126569},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050486},{"month":10,"riseRate":0.2,"avgChangeRate":-0.079168},{"month":11,"riseRate":0.4,"avgChangeRate":0.028843},{"month":12,"riseRate":0.2,"avgChangeRate":-0.000986}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}